淋巴癌診療指引

一、參院參與討論同仁

主席	謝耀宇 血液腫瘤科主任	
附設醫院	高冠鈞 血液腫瘤科主治醫師	李奕瑋 血液腫瘤科主治醫師
	黃巧雲 癌症中心個管師	
萬芳醫院	邱宗傑 血液腫瘤科主治醫師	張家崙 血液腫瘤科主治醫師
	劉興璟 血液腫瘤科主治醫師	謝宛蓁血液腫瘤科主治醫師
	吳正友 放射腫瘤科主治醫師	林暐棠 影像醫學部主治醫師
	劉育辰 癌症中心個管師	林惠庭 癌症中心個管師
雙和醫院	謝燿宇 血液腫瘤科主治醫師	蔡承志 血液腫瘤科主治醫師
	劉惠文 血液腫瘤科主治醫師	黃珮芳 癌症中心個管師

二、討論日期：114 年 10 月 23 日

三、校稿人員：張家崙 醫師 / 林惠庭 個管師

113 年原版

[淋巴癌診治共識 -6]一何杰金氏淋巴癌 (Hodgkin's Lymphoma) -

Classic Hodgkin's Lymphoma 第 III-IV 期之治療與追蹤 (年齡 18–60 歲)



114 年修訂版

[淋巴癌診治共識 -6]一何杰金氏淋巴癌 (Hodgkin's Lymphoma)-

Classic Hodgkin's Lymphoma 第 III-IV 期之治療與追蹤 (年齡 18–60 歲)。

1. 治療第 2 條路徑修改爲「AVD + (BV 或 Nivo) 6 療程」。
2. 路徑修改如下 :



113 年原版

[淋巴癌診治共識 -15] ─T 細胞淋巴癌 診斷檢查、分期治療



114 年修訂版

[淋巴癌診治共識 -15] ─T 細胞淋巴癌 診斷檢查、分期治療

1.「PTCL, NOS, ALCL, ALK(-) → 穩定」路徑，修改「觀察或自體移植」。

2. 路徑修改如下：



[淋巴癌診治共識 -1]—何杰金氏淋巴癌 (Hodgkin's Lymphoma)- 診斷檢查、分期與預後分類



1. B symptoms : fever, night sweating, body weight loss.
2. 預後不良因子 :ESR>50, B symptoms, Nodal sites >3. bulky tumor (≥ 10 cm) or large mediastinum lesion(MMR>0.33).
3. Clinical trial is always an option of treatment.

[淋巴癌診治共識 -2] Classical Hodgkin's Lymphoma (CHL) 臨床分期與預後分類

臨床分期	Bulky Mediastinal Disease or >10 cm Adenopathy	ESR>50 or #Sites>3	預後分類
IA / IIA	No	No	Favorable Disease
	No	Yes	Favorable /Unfavorable Disease
	Yes	Yes/No	Unfavorable Disease
IB / IIB	Yes / No	Yes/No	Unfavorable Disease
III - IV	Yes / No	N/A	Advanced Disease

PET 5-POINT SCALE (DEAUVILLE CRITERIA)

Score PET		CT Scan Result
Negative	1	No uptake(沒有顯影)
	2	Uptake ≤ mediastinum(有顯影 ,SUV ≤縱膈腔)
	3	Uptake > mediastinum but ≤ liver(有顯影 , SUV > 縱膈腔 但 ≤肝臟)
Positive	4	Uptake moderately higher than liver and visually above adjacent background activity(有顯影 , SUV 中度高於肝臟但比周圍背景值高)
	5	Uptake markedly higher than liver and/or new lesions(有顯影 ,SUV 明顯高於肝臟 或 / 和新病灶有顯影)
	X	New areas of uptake unlikely to be related to lymphoma(新的區域有顯影 , 不太可能與淋巴瘤有關)

[淋巴癌診治共識 -4]—何杰金氏淋巴癌 (Hodgkin's Lymphoma)- Classic Hodgkin's Lymphoma 早期預後良好分類之治療與追蹤 (年齡 18–60 歲)



1. Clinical trial is always an option of treatment.
2. Rituximab may be added electively (self-paid) if CD 20 is positive in IHC stain.
3. 早期預後良好定義 :1.Age< 50 y/o 2.ESR normal 3.Stage I~II 4.No B symptoms 5.No bulky disease
4. PET 評估若以 DEAUVILLE CRITERIA 計算，請依個案與核醫科醫師討論
5. PET 5-POINT SCALE (DEAUVILLE CRITERIA)，請參照 [淋巴癌診治共識 -3] 何杰金氏淋巴癌 (Hodgkin's Lymphoma)

[淋巴癌診治共識 -5]—何杰金氏淋巴癌 (Hodgkin's Lymphoma)- Classic Hodgkin's Lymphom 早期非預後良好分類之治療與追蹤 (年齡 18–60 歲)



1. Clinical trial is always an option of treatment.
2. 巨大腫瘤意指 bulky mediastinal disease or ≥ 10 cm.
3. PET 評估若以 DEAUVILLE CRITERIA 計算，請依個案與核醫科醫師討論
4. PET 5-POINT SCALE (DEAUVILLE CRITERIA)，請參照 [淋巴癌診治共識 -4] 何杰金氏症 (Hodgkin's Lymphoma)

[淋巴癌診治共識 -6]—何杰金氏淋巴癌 (Hodgkin's Lymphoma) - Classic Hodgkin's Lymphoma 第 III-IV 期之治療與追蹤 (年齡 18–60 歲)



---

1. Clinical trial is always an option of treatment.
2. 巨大腫瘤意指 bulky mediastinal disease or ≥ 10 cm.
3. PET 評估若以 DEAUVILLE CRITERIA 計算，請依個案與核醫科醫師討論
4. PET 5-POINT SCALE (DEAUVILLE CRITERIA)，請參照 [淋巴癌診治共識 -4] 何杰金氏症 (Hodgkin's Lymphoma)

* 化學治療至少 2 次療程再進行重新評估 (PET-CT)

** 總共 6 個療程

[淋巴癌診治共識 -7]—何杰金氏淋巴癌 (Hodgkin's Lymphoma) - Classic Hodgkin's Lymphoma (年齡 >60 歲 或 體力狀況不佳 或 有嚴重合併症的成年人治療方式)

* 治療原則 : 全身性治療

主要全身性治療方案	
早期預後良好分類	• A(B)VD 2 個療程 ± AVD 2 個療程 + 放射線治療 (首選)。 • CHOP 4 個療程 + 放射線治療。
早期非預後良好分類 或 第 III- IV 期	• A(B)VD 2 個療程→重新評估 PET-CT： 陰性→ AVD 4 個療程 。 陽性→個別化治療。 • BV 後進行 AVD，對完全反應或部分反應且無神經病變的患者有條件地進行 BV 治療。 • CHOP 6 個療程 ± 放射線治療。
心臟功能不佳	• Dexrazoxane + ABVD 或 CHOP (密切追蹤的心臟檢查) 。 • BV-DTIC (dacarbazine) 。

[淋巴癌診治共識 -8]—何杰金氏淋巴癌 (Hodgkin's Lymphoma)- Nodular lymphocyte–predominant Hodgkin's Lymphoma 分期治療與追蹤



---

* 化學治療至少 2 次再進行重新評估 (PET-CT)
˙Clinical trial is always an option of treatment. PET
*PET 評估若以 DEAUVILLE CRITERIA 計算，請依個案與核醫科醫師討論
*PET 5-POINT SCALE (DEAUVILLE CRITERIA)，請參照 [淋巴癌診治共識 -4] 何杰金氏症 (Hodgkin's Lymphoma)
*IPS: 評估第三或第四期何杰金氏淋巴癌的預後指標 - 危險因子項目 / 計算方式 (共 7 項): Serum albumin/ <4 g/dL；Hb /<10.5 g/dL; Male/yes；Stage IV/ yes；Age/ ≥ 45 y/o；WBC count/ ≥ 15k/mcL；Lymphocyte count/<600/mcL or <8% of WBC count。
* BV: Brentuximab vedotin。

[淋巴癌診治共識 -9] ─慢性淋巴細胞白血病 (CLL)/ 小淋巴細胞淋巴癌 (SLL) 診斷檢查、分期治療



- Clinical trial is always an option of treatment.
- 評估有以下症狀 *:
  1. Fatigue(severe) 2. Night sweats 3. Weight loss 4. Fever without infection
     * Threatened end-organ function
     * Progressive bulky disease(spleen>6cm below costal margin, lymph nodes>10cm)
     * Progressive anemia
     * Progressive thrombocytopenia
- Gazyva(Obinatuvzumab)(optional)

[淋巴癌診治共識 -10] —濾泡性淋巴癌 (Follicular Lymphoma)- Grade 1、2、3A
診斷檢查、分期治療



*Rituximab 持續性治療每三個月施打一次，持續 2 年，僅適用於濾泡性淋巴瘤 (Gr. 1-3) 。

・Clinical trial is always an option of treatment.

* 第 II 期相連病兆型：濾泡性淋巴癌細胞存在於彼此相鄰的淋巴結組中。

* 第 II 期不相連病兆型：濾泡性淋巴癌細胞見於橫隔膜同側的兩個或多個淋巴結群。

[淋巴癌診治共識 -11] ─瀰漫性大 B 細胞淋巴癌 (DLBCL)/ 濾泡性淋巴癌 (FL Grade 3B) 診斷檢查、分期治療



* Rituximab 持續性治療每三個月施打一次，持續 2 年，僅適用於濾泡性淋巴瘤 (Gr. 1-3)

• Clinical trial is always an option of treatment.

[淋巴癌診治共識 -12] —濾泡淋巴癌轉型成瀰漫性大 B 細胞淋巴癌 (FL　DLBCL) 治療



[淋巴癌診治共識 -13] ─胃黏膜淋巴組織相關淋巴癌 (Gastric MALT lymphoma) Lugano Staging

Lugano Staging System for Gastrointestinal Lymphomas		Lugano Modification of Ann Arbor Staging System	TNM Staging System Adapted for Gastric Lymphoma	Tumor Extension
Stage I	Confined to GI tract[a]			
	I_1 = mucosa, submucosa	I_E	T1 N0 M0	Mucosa, submucosa
	I_2 = muscularis propria, serosa	I_E	T2 N0 M0	Muscularis propria
		I_E	T3 N0 M0	Serosa
Stage II	Extending into abdomen			
	II_1 = local nodal involvement	II_E	T1-3 N1 M0	Perigastric lymph nodes
	II_2 = distant nodal involvement	II_E	T1-3 N2 M0	More distant regional lymph nodes
Stage IIE	Penetration of serosa to involve adjacent organs or tissues	II_E	T4 N0 M0	Invasion of adjacent structures
Stage IVB	Disseminated extranodal involvement or concomitant supradiaphragmatic nodal involvement		T1-4 N3 M0	Lymph nodes on both sides of the diaphragm/ distant metastases (eg, bone marrow or additional extranodal sites)
		IV	T1-4 N0-3 M1	

[淋巴癌診治共識 -14] —胃黏膜淋巴組織相關淋巴癌 (Gastric MALT lymphoma) 診斷檢查、分期治療



• Clinical trial is always an option of treatment.



1. Clinical trial is always an option of treatment.
2. Treatment with diffuse large B cell lymphoma without rituximab.
3. aaIPI: 年齡調整國際預後指數

《參考文獻》

1. NCCN clinical practice guidelines in oncology-Hodgkin Lymphoma. Version 3.2024.
2. NCCN clinical practice guidelines in oncology-B-cell Lymphoma. Version 3.2024.
3. NCCN clinical practice guidelines in oncology-T-cell Lymphoma. Version 4.2024.
4. NCCN clinical practice guidelines in oncology-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 4.2024.
5. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-3068.
6. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013;381:1817-1826.
7. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study)[abstract]. Blood 2014;124:Abstract 19.
8. Flinn IW, van der Jagt R, Kahl BS, et al. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. Blood 2014;123:2944-2952.
9. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-1210. Flinn IW, van der Jagt R, Kahl BS, et al. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. Blood 2014;123:2944-2952.
10. Salles, G, Seymour JF, Feugier P, et al. Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy [abstract]. Blood 2013;122:Abstract 509.
11. Radford J, et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin Lymphoma and a negative PET scan after 3 cycles of ABVD. esults of the UK NCRI RAPID Trial [abstract]. Blood 2012; 120:Abstract 547.

12. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209-3216. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine
13. Meyer R, Gospodarowicz M, Connors J, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012;366:399-408.
14. Salles GA, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. The Lancet 2011;377:42-51.
15. alles GA, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial. The Lancet 2011;377:42-51.
16. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-2045.
17. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
18. WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, et al., eds (ed 4). Lyon, France: IARC; 2008
19. Fernández de Larrea C, Martínez C, et al. Salvage chemotherapy with alternating MINE- ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem cell transplantation. Ann Oncol 2010;21(6):1211-1216.
20. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126.
21. NCCN clinical practice guidelines in oncology- Hodgkin Lymphoma. Version 1.2024.

《淋巴癌抗癌藥物治療指引》

115 年版與上一版差異

114 年版 修訂日 114/02/16	115 年版 修訂日 114/11/27
Hodgkin Lymphoma (Age ≥ 18 years)	Hodgkin Lymphoma
Classical Hodgkin Lymphoma	Classical Hodgkin Lymphoma (Age ≥ 18 years)
	■新增 ABVD followed by BrECADD ± ISRT
	■新增 Any Age and Not a Candidate for Anthracycline
	• BV + Nivolumab ± ISRT
	• Nivolumab ± ISRT
	• Pembrolizumab ± ISRT
	• BV + DTIC
Hodgkin Lymphoma (Age > 60 years)	Classical Hodgkin Lymphoma (Age > 60 years)
	■新增 Nivolumab + AVD
Systemic therapy for relapsed or refractory disease	Systemic therapy for relapsed or refractory disease
Second-Line or Subsequent Therapy Options	Second-Line or Subsequent Therapy Options
	■ 新增 GEMOX + Tislelizumab-jsgr
	■ 新增 Pembrolizumab + Vorinostat
	■ 新增 Pembrolizumab + Decitabine

114 年版 修訂日 114/02/16	115 年版 修訂日 114/11/27
Non-Hodgkin’s Lymphoma	Non-Hodgkin’s Lymphoma
Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma
Second-line Therapy (non-candidates for high-dose therapy)	Second-line Therapy (non-candidates for high-dose therapy) ■ 新增 Glofitamab-gxbm + GemOx ■ 新增 Epcoritamab-bysp + GemOx ■ 新增 Polatuzumab vedotin-piiq + mosunetuzumab-axgb ■ 新增 Tafasitamab+ lenalidomide
Second-line Therapy (relapsed disease <12 mo or primary refractory disease)	Second-line Therapy (relapsed disease <12 mo or primary refractory disease) ■ 新增 Glofitamab-gxbm + GemOx ■ 新增 Epcoritamab-bysp + GemOx ■ 新增 Polatuzumab vedotin-piiq + mosunetuzumab-axgb ■ 新增 Tafasitamab+ lenalidomide

《淋巴癌抗癌藥物治療指引》

Hodgkin Lymphoma

Classical Hodgkin Lymphoma (Age ≥ 18 years)

ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) ± ISRT

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W	4	1-4
Bleomycin	10 unit/m^2	≥ 15 mins	d1, 15	Q4W	4	
Vinblastine	6	≥ 5 mins	d1, 15	Q4W	4	
Dacarbazine	375	1 hr	d1, 15	Q4W	4	

Brentuximab vedotin+AVD (Doxorubicin+ Vinblastine+ Dacarbazine)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.2 mg/kg	30 mins	d1, 15	Q4W	6	5
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W	6	
Vinblastine	6	≥ 5 mins	d1, 15	Q4W	6	
Dacarbazine	375	1 hr	d1, 15	Q4W	6	

Nivolumab + AVD (Doxorubicin+ Vinblastine+ Dacarbazine)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg*	≥ 30 mins	d1, 15	Q4W	6	6
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W	6	
Vinblastine	6	≥ 5 mins	d1, 15	Q4W	6	
Dacarbazine	375	1 hr	d1, 15	Q4W	6	

*3 mg/kg for 12~18 y/o

ABVD followed by BrECADD ± ISRT

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W	2	7
Bleomycin	10 unit/m2	≥ 15 mins	d1, 15	Q4W	2	
Vinblastine	6	≥ 5 mins	d1, 15	Q4W	2	
Dacarbazine	375	1 hr	d1, 15	Q4W	2	
Followed by						
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	4-6	
Etoposide	150 → 125 → 100	≥ 30 mins	d2-4	Q3W		
Doxorubicin	40 → 35	≥ 5 mins	d2	Q3W		
Cyclophosphamide	1250→1100→950 → 800 → 650	≥ 30 mins	d2	Q3W		
Dacarbazine	250	1 hr	d3-4	Q3W		
Dexamethasone	40 mg PO QD		d2-5	Q3W		

BrECADD (BV, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, Dexamethasone) ± ISRT

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	4-6	7
Etoposide	150	≥ 30 mins	d2-4	Q3W		
Doxorubicin	40	≥ 5 mins	d2	Q3W		
Cyclophosphamide	1250	≥ 30 mins	d2	Q3W		
Dacarbazine	250	1 hr	d3-4	Q3W		
Dexamethasone	40 mg PO QD		d2-5	Q3W		

參考文獻

1. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD 11 trial. J Clin Oncol 2010;28:4199-4206.
2. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
3. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography–negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014;32:1188-1194.
4. Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015;372:1598-1607.Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704.
5.Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. New England Journal of Medicine. 2018;378(4):331-344.
6. Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med 2024;391:1379-1389
7. Borchmann P, Ferdinandus J, Schneider G, et al. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. Lancet. 2024 Jul 27;404(10450):341-352. doi: 10.1016/S0140-6736(24)01315-1. Epub 2024 Jul 3. Erratum in: Lancet. 2024 Nov 30;404(10468):2164. doi: 10.1016/S0140-6736(24)02571-6. PMID: 38971175.

Classical Hodgkin Lymphoma (Age > 60 years)

A(B)VD ± ISRT

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W	#	1-4, 7
Bleomycin*	10 unit/m^2	≥ 15 mins	d1, 15	Q4W	#	
Vinblastine	6	≥ 5 mins	d1, 15	Q4W	#	
Dacarbazine	375	1 hr	d1, 15	Q4W	#	

* Bleomycin should be used with caution as it may not be tolerated in older adults.

[#] A(B)VD (2 cycles) followed by AVD (4 cycles), if PET scan is negative after 2 cycles of ABVD. If stage I-II unfavorable, consider a total of 4 cycles

CHOP ± ISRT

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	*	5
Doxorubicin	50	≥ 5 mins	d1	Q3W	*	
Vincristine	1.4	≥ 5 mins	d1	Q3W	*	
Prednisone	40[#]		d1-5	Q3W	*	

*Stage I-II favorable disease: 4; Stage I-II favorable or III-IV: 6

[#] or 100 mg/day

Brentuximab vedotin followed by AVD, conditionally followed by brentuximab vedotin in responding patients with CR or PR

The first lead-in phase

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	2	8

The second phase

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W	6	8
Vinblastine	6	≥ 5 mins	d1, 15	Q4W	6	
Dacarbazine	375	1 hr	d1, 15	Q4W	6	

The third phase

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	4	8

Stage I-II unfavorable or III-IV

Brentuximab vedotin + DTIC (dacarbazine) (for low EF patient)

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	12	9, 10
Dacarbazine	375	1 hr	d1	Q3W	12	
Followed by						
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	13-16 or more	

Stage I-II unfavorable or III-IV

Nivolumab + AVD

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg or 3 mg/kg	≥ 30 mins	d1, 15	Q4W	6	16
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W	6	
Vinblastine	6	≥ 5 mins	d1, 15	Q4W	6	
Dacarbazine	375	1 hr	d1, 15	Q4W	6	

Relapsed or Refractory Disease

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Bendamustine	120	30 mins	d1, 2	Q4W		11

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	12	12

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q2W		13, 14

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	10 mg/kg	≥ 30 mins	d1	Q2W		15

參考文獻

1. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652.
2. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015;170:179-184.
3. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015;385:1418-1427.
4. Johnson P, Federico M, Fossa A, et al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK/07/033) [abstract]. Hematol Oncol 2015;33 (Suppl S1):Abstract 008.
5. Kolstad A, Nome O, Delabie J, et al. Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007;48:570-576.
6. Boll B, Bredenfeld H, Gorgen H, et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011;118:6292-6298.
7. Johnson P, Federico M, Fossa A, et al. Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK/07/033) [abstract]. Hematol Oncol 2015;33 (Suppl S1): Abstract 008.

8. Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 2018;36:3015-3022.
9. Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.Blood 2017;130:2829-2837
10. Friedberg JW, Forero-Torres A, Holkova B, et al. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma [abstract]. J Clin Oncol 2018;36 (Suppl 15): Abstract 7542.
11. Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456-460.
12. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-2189.
13. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
14. Timmerman J, Armand P, Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: Updated results of a phase 1 study (CA 209-039) [abstract]. Hematol Oncol 2015;33:Abstract 010.
15. Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013) [abstract]. Blood 2014;124:Abstract 290.
16. Brockelmann PJ, Buhnen I, Meissner J, et al. Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: Final analysis of the Randomized German Hodgkin Study Group phase II NIVAHL trial. J Clin Oncol 2023;41:1193-1199

Any Age and Not a Candidate for Anthracycline

Stage I–IV

BV + Nivolumab ± ISRT

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	16	1
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q3W	16	

Nivolumab ± ISRT (if contraindications to BV)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q2W		2, 3

Pembrolizumab ± ISRT (if contraindications to BV)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		4, 5

BV + DTIC

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	12	6, 7
Dacarbazine	375	1 hr	d1	Q3W	12	
Followed by						
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W	13-16 or more	

參考文獻

1.Friedberg JW, Bordoni R, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood 21 2024;143:786-795
2. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
3. Timmerman J, Armand P, Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: Updated results of a phase 1 study (CA 209-039) [abstract]. Hematol Oncol 2015;33:Abstract 010.
4. Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X.
5. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125-2132.
6. Friedberg JW, Forero-Torres A, Bordoni RE, et al. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.Blood 2017;130:2829-2837
7. Friedberg JW, Forero-Torres A, Holkova B, et al. Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma [abstract]. J Clin Oncol 2018;36 (Suppl 15): Abstract 7542.

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Doxorubicin	25	≥ 5 mins	d1, 15	Q4W		1, 2
Bleomycin	10 unit/m2	≥ 15 mins	d1, 15	Q4W		
Vinblastine	6	≥ 5 mins	d1, 15	Q4W		
Dacarbazine	375	1 hr	d1, 15	Q4W		
± Rituximab	375	★	d1	Q4W		

CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cyclophosphamide	750	≥ 30 mins	d1	Q3W		3
Doxorubicin	50	≥ 5 mins	d1	Q3W		
Vincristine	1.4	≥ 5 mins	d1	Q3W		
Prednisone	40 mg/day PO		d1-5	Q3W		
± Rituximab	375	★	d1	Q3W		

CVP (Cyclophosphamide, Vinblastine, Prednisone) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Cyclophosphamide	500	≥ 30 mins	d1	Q2-3W		4
Vinblastine	6	≥ 5 mins	d1, 8	Q2-3W		
Prednisone	40 mg/day PO		d1-7	Q2-3W		
± Rituximab	375	★	d1	Q2-3W		

Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	QW		5-9

★ **Rituximab infusion rate:** max 400 mg/h

1st dose: initial 50 mg/h, increase 50 mg/h every 30 mins (if no infusion reaction)

2nd and after dose: initial 100 mg/h, increase 100 mg/h every 30 mins (if no infusion reaction)

參考文獻

1. Savage KJ, Skinnider B, AI-Mansour M, et al. Treating limited stage nodular lymphocyte predominat Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 2011;118:4585-4590.
2. Canellos GP, Mauch P. What is the appropriate systemic chemotherapy for lymphocyte-predominat Hodgkin's Lymphoma? J Clin Oncol 2010;28:e8.
3. Fanale MA, Lai C-M, McLaughlin P, et al. Outcomes of Nodular Lymphocyte Predominat Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. ASH Annual Meeting Abstracts 2010;116:2812.
4. Shankar A, Hall GW, Gorde-Grosjean S, et al. Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. Eur J Cancer 2012;48:1700-1706.
5. Advani RH, Hoppe RT. How I treat nodular lymphocyte predominant Hodgkin lymphoma. Blood 2013;122:4182-4188.
6. Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 2014;32:912-918.
7. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008;111(1):109-111.
8. Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 2011;118:4363-4365.
9. Eichenauer DA, Plutschow A, Fuchs M, et al. Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. J Clin Oncol 2015;33:2857-2862.

Systemic therapy for relapsed or refractory disease

Second-Line or Subsequent Therapy Options

CHL

DHAP (Dexamethasone, Cisplatin, high-dose Cytarabine)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3-4W		1, 2
Cisplatin	100	22-24 hrs	d1	Q3-4W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3-4W		

ESHAP (Etoposide, Methylprednisolone, Cisplatin, high-dose Cytarabine)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Methylprednisolone	500 mg	≥ 30 mins	d1-5	Q3-4W		3, 4, 5
Etoposide	40	30-60 mins	d1-4	Q3-4W		
Cisplatin	25	21-24 hrs	d1-4	Q3-4W		
Cytarabine	2000	≥ 1 hr	d5	Q3-4W		

Gemcitabine/Bendamustine/Vinorelbine

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	800	30 mins	d1, 4	Q3W	4	22
Bendamustine	100	30-60 mins	d2, 3	Q3W	4	
Vinorelbine	20	6-10 mins	d1	Q3W	4	
Prednisolone	100 mg/day PO		d1-4	Q3W	4	

GCD (Gemcitabine, Carboplatin, Dexamethasone)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W		6, 7
Carboplatin	AUC 5	1 hr	d1	Q3W		
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3W		

GVD (Gemcitabine, Vinorelbine, Lipo-Doxorubicin)

For transplant- naïve patients

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1, 8	Q3W		8
Vinorelbine	20	6-10 mins	d1, 8	Q3W		
Lipo-Doxorubicin	15	≥ 30 mins	d1, 8	Q3W		

For post-transplant patients

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	800	30 mins	d1, 8	Q3W		8
Vinorelbine	15	6-10 mins	d1, 8	Q3W		
Lipo-Doxorubicin	10	≥ 30 mins	d1, 8	Q3W		

GVD + Pembrolizumab (Transplant eligible patients)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W	2-4	28
Gemcitabine	1000	30 mins	d1, 8	Q3W		
Vinorelbine	20	6-10 mins	d1, 8	Q3W		
Lipo-Doxorubicin	15	≥ 30 mins	d1, 8	Q3W		

ICE (Ifosfamide, Carboplatin, Etoposide)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Etoposide	100	30-60 mins	d1-3	Q3W		9, 10
Carboplatin	AUC 5	1 hr	d2	Q3W		
Ifosfamide*	5000	24 hrs	d2	Q3W		

*Plus Mesna with same dose of Ifosfamide

ICE + Brentuximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab	1.5 mg/kg*	30 mins	d1*	Q3W		29
Etoposide	100	30-60 mins	d1-3	Q3W		
Carboplatin	AUC 5	1 hr	d2	Q3W		
Ifosfamide#	5000	24 hrs	d2	Q3W		

*capped at 150 mg; Dose-dense: on d1, 8

#Plus Mesna with same dose of Ifosfamide

ICE + Nivolumab (bridging most patients to AHCT)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	≥ 30 mins	d1	Q2W	Up to 6	30
Etoposide	100	30-60 mins	d1-3	Q3W		
Carboplatin	AUC 5	1 hr	d2	Q3W		
Ifosfamide*	5000	24 hrs	d2	Q3W		

* Plus Mesna with same dose of Ifosfamide

ICE + Pembrolizumab (eligible for an autologous stem cell transplant)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		34
Etoposide	100	30-60 mins	d1-3	Q3W		
Carboplatin	AUC 5	1 hr	d2	Q3W		
Ifosfamide*	5000	24 hrs	d2	Q3W		

* Plus Mesna with same dose of Ifosfamide

GEMOX + Tislelizumab-jsgr

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1	Q3W	6-8	36
Oxaliplatin	100	2 hrs	d1	Q3W	6-8	
Tislelizumab -jsgr	200 mg	90 → 60 → 30 mins	d2	Q3W	For 2 years	

IGEV (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Ifosfamide*	2000	24 hrs	d1-4	Q3W		11
Gemcitabine	800	30 mins	d1, 4	Q3W		
Vinorelbine	20	6-10 mins	d1	Q3W		
Prednisolone	100 mg/day PO		d1-4	Q3W		

* Plus Mesna with same dose of Ifosfamide

Mini-BEAN (Carmustine, Cytarabine, Etoposide, Mephalan)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Carmustine	60	1 hr	d1	Q4-6W		12, 13
Cytarabine	100 BID	≥ 30 mins	d2-5	Q4-6W		
Etoposide	75	1 hr	d2-5	Q4-6W		
Mephalan	30	≥ 30 mins	d6	Q4-6W		

MINE (Etoposide, Ifosfamide, Mesna, Mitoxantrone)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Mesna	1300	1 hr	d1-3	Q3-4W		14
Ifosfamide	1300	1 hr	d1-3	Q3-4W		
Mitoxantrone	8	≥ 5 mins	d1	Q3-4W		
Etoposide	65	1 hr	d1-3	Q3-4W		

Brentuximab vedotin (only for CHL)

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin*	1.8 mg/kg	30 mins	d1	Q3W		15

*alone or in combination with the second-line regimens below

Brentuximab vedotin + Bendamustine

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W		23
Bendamustine	90 (70-90)	30-60 mins	d1, 2	Q3W		

Brentuximab vedotin + Nivolumab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab vedotin	1.8 mg/kg	30 mins	d1	Q3W		24
Nivolumab	3 mg/kg	≥ 30 mins	d8	Q3W	1st	
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q3W	2nd~4th	

Additional Therapy Options: (only for CHL)

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Bendamustine	120	30-60 mins	d1, 2	Q4W		16

藥品名	劑量 mg/m²	給藥日	頻率	週期	參考文獻
Everolimus	10 mg PO QD				17

藥品名	劑量 mg/m^2	給藥日	頻率	週期	參考文獻
Lenalidomide	25 mg PO QD	d1-21	Q4W		18

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	≥ 30 mins	d1	Q2W		19, 20

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	10 mg/kg	≥ 30 mins	d1	Q2W		21

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q2W		31, 32

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Vinblastine	0.1 mg/kg	≥ 5 mins	d1	Q2W		33

Bendamustine + Carboplatin + Etoposide (CD20(+) + Rituximab 375 mg/m^2)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Bendamustine	60-120	30-60 mins	d1, 2	Q3W		25
Carboplatin	AUC 5*	1 hr	d1	Q3W		
Etoposide	100	1 hr	d1-3	Q3W		

* capped at 800 mg

Gemcitabine + Oxaliplatin

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	30 mins	d1	Q2W or Q3W		26
Oxaliplatin	100	2 hrs	d1	Q2W or Q3W		

Pembrolizumab + Vorinostat

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	≥ 30 mins	d1	Q3W		37
Vorinostat	200 BID PO		d1-5, 8-12			

Pembrolizumab + Decitabine

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Decitabine	10 mg	≥ 1 hr	d1-5	Q3W		38-40
Pembrolizumab	200 mg	≥ 30 mins	d8	Q3W		

NLPHL

DHAP (Dexamethasone, Cisplatin, high-dose Cytarabine) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1			1, 2
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3-4W		
Cisplatin	100	22-24 hrs	d1	Q3-4W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3-4W		

ESHAP (Etoposide, Methylprednisolone, Cisplatin, high-dose Cytarabine) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1			3, 4, 5
Etoposide	40	≥ 30 mins	d1-4	Q3-4W		
Methylprednisolone	500 mg	30-60 mins	d1-4	Q3-4W		
Cisplatin	25	21-24 hrs	d1-4	Q3-4W		
Cytarabine	2000	≥ 1 hr	d5	Q3-4W		

ICE (Ifosfamide, Carboplatin, Etoposide) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1			9, 10
Etoposide	100	30-60 mins	d1-3	Q3W		
Carboplatin	AUC 5	1 hr	d2	Q3W		
Ifosfamide*	5000	24 hrs	d2	Q3W		

* Plus Mesna with same dose of Ifosfamide

IGEV (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1			11
Ifosfamide*	2000	24 hrs	d1-4	Q3W		
Gemcitabine	800	30 mins	d1, 4	Q3W		
Vinorelbine	20	6-10 mins	d1	Q3W		
Prednisolone	100 mg/day PO		d1-4	Q3W		

* Plus Mesna with same dose of Ifosfamide

Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	QW	4	35

R-Bendamustine

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Bendamustine	90	30-60 mins	d1, 2	Q3W		27
Rituximab	375	★	d1			

★ **Rituximab infusion rate:** max 400 mg/h

1st dose: initial 50 mg/h, increase 50 mg/h every 30 mins (if no infusion reaction)

2nd and after dose: initial 100 mg/h, increase 100 mg/h every 30 mins (if no infusion reaction)

參考文獻

1. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13(10):1628-1635.
2. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, et al. Comparison of ICE (ifosfamide-carboplatinetoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26(4):401-406.
3. Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10(5):593-595.
4. Fernández de Larrea C, Martínez C, et al. Salvage chemotherapy with alternating MINEESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem cell transplantation. Ann Oncol 2010;21(6):1211-1216.
5. Labrador J, Cabrero-Calvo M, Perez-Lopez E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma.

Ann Hematol 2014;93:1745-1753.
6. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014;32:3490-3496.
7. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemicitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523-1529.
8. Bartlett N, Niedzwiecki D, Johnson J, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007;18(6):1071-1079.
9. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97(3):616-623.
10. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, et al. Comparison of ICE (ifosfamide-carboplatinetoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26(4):401-406.
11. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007;92(1):35-41.
12. Colwill R, Crump M, Couture F, et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396-402.
13. Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol 2001;113(1):161-171.
14. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphoms. Ann Oncol 1995;6(6):609-611.
15. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-2189.
16. Moskowitz AJ, Hamlin PA, Perales M-A, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31:456-460.

17. Johnston PB, Inwards DJ, Colgan JP, et al; A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-4.
18. Fehniger TA, Larson S, Trinkaus K, et al; A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118(19):5119-25.
19. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9.
20. Timmerman J, Armand P, Lesokhin AM, et al. Nivolumab in patients with relapsed or refractory lymphoid malignancies and classical Hodgkin lymphoma: Updated results of a phase 1 study (CA 209-039) [abstract]. Hematol Oncol 2015;33:Abstract 010.
21. Moskowitz CH, Ribrag V, Michot J-M, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013) [abstract]. Blood 2014;124:Abstract 290.
22. Santoro A,Mazza R, Pulsoni A, et al.Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.J Clin Oncol 201634;3293-3299.
23. O'Connor OA, Lue JK, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial.Lancet Oncol 2018; 19: 257–66.
24. Herrera AF, Moskowitz AJ, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.Blood (2018) 131 (11): 1183–1194.
25. Budde LE, Wu D, Martin DB, et al. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 2018;183:601-607.
26. Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma. Onco Targets Ther 2014;7:2093-2100.
27. Prusila REI, Haapasaari KM, Marin K, et al. R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma. Acta Oncol 2018;57:1265-1267.
28. Moskowitz AJ, Shah G, Schöder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal

doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021:39:3109-3117.
29. Lynch RC, Cassaday RD, Smith SD, et al. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematol 2021;8:e562-e571.
30. Mei MG, Lee HJ, Palmer J, et al. Response-adapted anti-PD1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood 2022;139:3605-3616.
31. Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021 Apr;22(4):512-524.
32. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35:2125-2132.
33. Neoplastic disease. Treatment with vinblastine. A cooperative study. Arch Intern Med1965;116:856-852.
34. Bryan LJ, Casulo C, Allen PB, et al. Pembrolizumab added to ifosfamide,carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: A multi-institutional phase 2 investigator-initiated nonrandomized clinical trial. JAMA Oncol 2023;9:683-691.
35. Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte–Predominant Hodgkin Lymphoma.DOI: 10.1200/JCO.2013.53.2069 Journal of Clinical Oncology 32, no. 9 (March 20, 2014) 912-918.
36. Ding K, Liu H, Ma J, et al. Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica 2023;108:2146-2154.
37. Mei M, Chem L, Godfrey J, et al. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood. 2023;142:1359-1370.
38. Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol. 2019;37:1479-1489.
39. Lui Y, Wang C, Li X, et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. J Immunother Cancer 2021;9:e002347.
40. Wang C, Liu Y, Dong L, et al. Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy. Clin Cancer Res. 2021;27:2782-2791

Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma

First-line Therapy

★ **Rituximab infusion rate:** max 400 mg/h

1st dose: initial 50 mg/h, increase 50 mg/h every 30 mins (if no infusion reaction)

2nd and after dose: initial 100 mg/h, increase 100 mg/h every 30 mins (if no infusion reaction)

RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6	1-3
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	6	
Doxorubicin	50	≥ 5 mins	d1	Q3W	6	
Vincristine	1.4	≥ 5 mins	d1	Q3W	6	
Prednisone	100 mg/day PO		d1-5	Q3W	6	

Dose-dense RCHOP 14

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q2W	6	4
Cyclophosphamide	750	≥ 30 mins	d1	Q2W	6	
Doxorubicin	50	≥ 5 mins	d1	Q2W	6	
Vincristine	1.4	≥ 5 mins	d1	Q2W	6	
Prednisone	100 mg/day PO		d1-5	Q2W	6	

Dose- adjusted EPOCH + Rituximab

(Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) + Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6-8	5, 6
Etoposide	50	22 hrs	d1-4	Q3W	6-8	
Doxorubicin	10	22 hrs	d1-4	Q3W	6-8	
Vincristine	0.4	22 hrs	d1-4	Q3W	6-8	
Cyclophosphamide	750	1 hr	d5	Q3W	6-8	
Prednisone	60		d1-5	Q3W	6-8	

Pola-R-CHP (Polatuzumab vedotin-piiq, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Polatuzumab	1.8 mg/kg	90 → 30 mins	d1	Q3W	8	33
Rituximab	375	★	d1	Q3W	6	
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	6	
Doxorubicin	50	≥ 5 mins	d1	Q3W	6	
Prednisone	100 mg		d1-5	Q3W	6	

First-line Therapy for Patients with Poor Left Ventricular Function

CDOP (Cyclophosphamide, Lipo-Doxorubicin, Vincristine, Prednisone) + Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6-8	7, 8
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	6-8	
Lipo-Doxorubicin	30	2 hrs	d1	Q3W	6-8	
Vincristine	1.4	≥ 5 mins	d1	Q3W	6-8	
Prednisone	60 PO		d1-5	Q3W	6-8	

RGCVP (Rituximab, Gemcitabine, Cyclophosphamide, Vincristine, Prednisone)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6	10
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	6	
Gemcitabine	750-1000	30 mins	d1,8	Q3W	6	
Vincristine	1.4	≥ 5 mins	d1	Q3W	6	
Prednisone	100 mg PO		d1-5	Q3W	6	

DA-EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) + Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6-8	5, 6
Etoposide	50	22 hrs	d1-4	Q3W	6-8	
Doxorubicin	10	22 hrs	d1-4	Q3W	6-8	
Vincristine	0.4	22 hrs	d1-4	Q3W	6-8	
Cyclophosphamide	750	1 hr	d5	Q3W	6-8	
Prednisone	60 PO		d1-5	Q3W	6-8	

RCEOP (Rituximab, Cyclophosphamide, Etoposide, Vincristine, Prednisone)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	*	9
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	*	
Etoposide	50	1 hr	d1	Q3W	*	
Etoposide	100 PO		d2, 3	Q3W	*	
Vincristine	1.4	≥ 5 mins	d1	Q3W	*	
Prednisone	100 mg PO		d1-5	Q3W	*	

*limited stage: 3~4, advanced stage: 6

TREC (Rituximab, Bendamustine, Etoposide, Carboplatin)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	2	15
Bendamustine	90-120	30 mins	d1-2	Q3W	2	
Etoposide	100	1 hr	d1-3	Q3W	2	
Carboplatin	AUC 5	1 hr	d1	Q3W	2	

Patients >80years of age with comorbidities

R-mini-CHOP

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6	11
Cyclophosphamide	400	≥ 30 mins	d1	Q3W	6	
Doxorubicin	25	≥ 5 mins	d1	Q3W	6	
Vincristine	1 mg	≥ 5 mins	d1	Q3W	6	
Prednisone	40 PO		d1-5	Q3W	6	

R-COP

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W		23, 24
Cyclophosphamide	750	≥ 30 mins	d1	Q3W		
Vincristine	1.4 mg	≥ 5 mins	d1	Q3W		
Prednisone	100 PO		d1-5	Q3W		

RGCVP (Rituximab, Gemcitabine, Cyclophsphamide, Vincristine, Prednisolone)

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6	10
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	6	
Gemcitabine	750	30 mins	d1, 8	Q3W	6	
Vincristine	1.4	≥ 5 mins	d1	Q3W	6	
Prednisone	100 mg PO		d1-5	Q3W	6	

CDOP (Cyclophosphamide, Lipo-Doxorubicin, Vincristine, Prednisone) + Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W	6-8	7, 8
Cyclophosphamide	750	≥ 30 mins	d1	Q3W	6-8	
Lipo-Doxorubicin	30	2 hrs	d1	Q3W	6-8	
Vincristine	1.4	≥ 5 mins	d1	Q3W	6-8	
Prednisone	60 PO		d1-5	Q3W	6-8	

Concurrent presentation with CNS disease

Parenchymal

3 g/m² or more of systemic Methotrexate given on Day 15 of a 21-day RCHOP cycle that has been supported by growth factors.

Leptomeningeal

IT methotrexate/cytarabine, consider Ommaya reservoir placement and/or systemic methotrexate (3-3.5 g/m^2)

Second-line Therapy and Subsequent Therapy (intention to proceed to high-dose therapy)

★ **Infusion rate of Rituximab:** max 400 mg/h

1st dose: initial 50 mg/h, increase 50 mg/h every 30 min (if no infusion reaction)

2nd and after dose: initial 100 mg/h, increase 100 mg/h every 30 min (if no infusion reaction)

DHAP (Dexamethasone, Cisplatin, Cytarabine) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3-4W		12
Cisplatin	100	22-24 hrs	d1	Q3-4W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3-4W		
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3-4W		

DHAX (Dexamethasone, Cytarabine, oxaliplatin) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3W		25
Oxaliplatin	100	2 hrs	d1	Q3W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3W		
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3W		

DHAX (Dexamethasone, Cytarabine, Carboplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3W		32
Carboplatin	AUC 5	1 hr	d1	Q3W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3W		
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3W		

ESHAP (Etoposide, Methylprednisolone, Cytarabine, Cisplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3-4W		13
Etoposide	40	1 hr	d1-4	Q3-4W		
Methylprednisolone	500 mg	30-60 mins	d1-4	Q3-4W		
Cisplatin	25	21-24 hrs	d1-4	Q3-4W		
Cytarabine	2000	≥ 1 hr	d5	Q3-4W		

GDP (Gemcitabine, Dexamethasone, Cisplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d8	Q3W		19
Gemcitabine	1000	30 mins	d1, 8	Q3W		
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3W		
Cisplatin	75	≥ 4 hrs	d1	Q3W		

GDP (Gemcitabine, Dexamethasone, Carboplatin) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d8	Q3W		14
Gemcitabine	1000	30 mins	d1, 8	Q3W		
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3W		
Carboplatin	AUC 5	1 hr	d1	Q3W		

GemOx (Gemcitabine, Oxaliplatin) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q2-3W		15, 22
Gemcitabine	1000	30 mins	d2	Q2-3W		
Oxaliplatin	100	2 hrs	d2	Q2-3W		

ICE (Ifosfamide, Carboplatin, Etoposide) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q2W		12
Etoposide	100	30-60 mins	d1-3	Q2W		
Carboplatin	AUC 5	1 hr	d2	Q2W		
Isofamide*	5000	24 hrs	d2	Q2W		

* Plus Mesna with same dose of Ifosfamide

MINE (Mesna, Ifosfamide, Mitoxatrone, Etoposide) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3-4W		17
Mesna	1330	1 hr	d1-3	Q3-4W		
Isofamide	1330	1 hr	d1-3	Q3-4W		
Mitoxantrone	8	≥ 5 mins	d1	Q3-4W		
Etoposide	65	1 hr	d1-3	Q3-4W		

Second-line Therapy (non-candidates for high-dose therapy)

★ **Infusion rate of Rituximab & Obinutuzumab:** max 400 mg/h

1st dose: initial 50 mg/h, increase 50 mg/h every 30 min (if no infusion reaction)

2nd and after dose: initial 100 mg/h, increase 100 mg/h every 30 min (if no infusion reaction)

Glofitamab-gxbm + GemOx

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Obinutuzumab	1000 mg	★	d1	Q3W	1st	35
Gemcitabine	1000	30 mins	d2	Q3W	1st	
Oxaliplatin	100	2 hrs	d2	Q3W	1st	
Glofitamab	2.5 mg	≥ 4 hrs*	d8	Q3W	1st	
Glofitamab	10 mg	≥ 4 hrs*	d15	Q3W	1st	
Followed by						
Gemcitabine	1000	30 mins	d1	Q3W	2nd -8th	
Oxaliplatin	100	2 hrs	d1	Q3W	2nd -8th	
Glofitamab	30 mg	≥ 4 → 2 hrs*	d1	Q3W	2nd -8th	
Followed by						
Glofitamab	30 mg	2 hrs	d1	Q3W	9th -12th	

*over 4 hours in cycle 1&2, 2 hours in cycle 3-12

Epcoritamab-bysp + GemOx

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Epcoritamab	0.16 mg SC		d1	Q4W	1st	36
Gemcitabine	1000	30 mins	d2	Q4W	1st	
Oxaliplatin	100	2 hrs	d2	Q4W	1st	
Epcoritamab	0.8 mg SC		d8	Q4W	1st	
Epcoritamab	48 mg SC		d15, 22	Q4W	1st	
Followed by						
Epcoritamab	48 mg SC		d1, 8, 15, 22	Q4W	2^{nd} -3^{rd}	
Gemcitabine	1000	30 mins	d1, 15	Q4W	2^{nd} -3^{rd}	
Oxaliplatin	100	2 hrs	d1, 15	Q4W	2^{nd} -3^{rd}	
Followed by						
Epcoritamab	48 mg SC		d1, 15	Q4W	4^{th}	
Gemcitabine	1000	30 mins	d1, 15	Q4W	4^{th}	
Oxaliplatin	100	2 hrs	d1, 15	Q4W	4^{th}	
Followed by						
Epcoritamab	48 mg SC		d1, 15	Q4W	5^{th}-9^{th}	
Followed by						
Epcoritamab	48 mg SC		d1	Q4W	10^{th} and after	

Polatuzumab vedotin-piiq + mosunetuzumab-axgb

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Mosunetuzumab	1 mg	≥ 4 hrs	d1	Q3W	1st	37
Polatuzumab vedotin-piiq	1.8 mg/kg	90 mins	d1	Q3W		
Mosunetuzumab	2 mg	≥ 4 hrs	d8	Q3W	1st	
Mosunetuzumab	60 mg	≥ 4 hrs	d15	Q3W	1st	
Followed by						
Mosunetuzumab	60 mg	≥ 2 hrs	d1	Q3W	2nd	
Polatuzumab vedotin-piiq	1.8 mg/kg	30 mins	d1	Q3W	2nd	
Followed by						
Mosunetuzumab	30 mg	≥ 2 hrs	d1	Q3W	3rd -6th	
Polatuzumab vedotin-piiq	1.8 mg/kg	30 mins	d1	Q3W	3rd -6th	
Followed by						
Mosunetuzumab	30 mg	≥ 2 hrs	d1	Q3W	7th and after	

Tafasitamab(CD19)+ lenalidomide

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Tafasitamab	12 mg/kg	90-150 mins*	d1, 4, 8, 15, 22	Q4W	1st	38
lenalidomide	25mg/day PO		d1-21	Q4W	1st	
Tafasitamab	12 mg/kg	90-120 mins*	d1,8, 15, 22	Q4W	2nd-3rd	
lenalidomide	25mg/day PO		d1-21	Q4W	2nd-3rd	
Tafasitamab	12 mg/kg	90-120 mins*	d1,15	Q4W	4th -12th	
lenalidomide	25mg/day PO		d1-21	Q4W	4th -12th	
Tafasitamab	12 mg/kg	90-120 mins*	d1,15	Q4W	13th and after	

* 70mL/h for the first 30 mins, then increase the rate

CEOP (Cyclophosphamide, Etoposide, Vincristine, Prednisone) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3W		16
Cyclophosphamide	750	≥ 30 mins	d1	Q3W		
Etoposide	50	1 hr	d1	Q3W		
Etoposide	100 PO		d2-3	Q3W		
Vincristine	1.4	≥ 5 mins	d1	Q3W		
Prednisone	100		d1-5	Q3W		

DA-EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) + Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	Q3W		18
Etoposide	50	22 hrs	d1-4	Q3W		
Doxorubicin	10	22 hrs	d1-4	Q3W		
Vincristine	0.4	22 hrs	d1-4	Q3W		
Cyclophosphamide	750	1 hr	d5	Q3W		
Prednisone	60		d1-5	Q3W		

GDP (Gemcitabine, Dexamethasone, Cisplatin) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d8	Q3W		19
Gemcitabine	1000	30 mins	d1, 8	Q3W		
Dexamethasone	40 mg	10-15 mins	d1-4	Q3W		
Cisplatin	75	≥ 4 hrs	d1	Q3W		

GDP (Gemcitabine, Dexamethasone, Carboplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d8	Q3W		14
Gemcitabine	1000	30 mins	d1, 8	Q3W		
Dexamethasone	40 mg	10-15 mins	d1-4	Q3W		
Carboplatin	AUC 5	1 hr	d1	Q3W		

GemOx (Gemcitabine, Oxaliplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q2W		20
Gemcitabine	1000-1200	30 mins	d1	Q2W		
Oxaliplatin	100-120	2 hrs	d2	Q2W		

Lenalidomide ± Rituximab (non-GCB DLBCL)

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q4W		26
Lenalidomide	20		d1-21	Q4W		

Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Rituximab	375	★	d1	QW		21

Bendamustine, Rituximab, Polatuzumab vedotin-piiq

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Polatuzumab vedotin-piiq	1.8 mg/kg	90 → 30 mins	d1	Q3W	6	28
Bendamustine	90	30-60 mins	d1, 2	Q3W	6	
Rituximab	375	★	d1	Q3W	6	

Brentuximab for CD30+ disease

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Brentuximab	1.8 mg/kg	30 mins	d1	Q3W		27

Ibrutinib (non GCB-DLBCL)

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Ibrutinib	560 mg PO QD		d1	Q3W		29

Second-line Therapy (relapsed disease <12 mo or primary refractory disease)

★ **Infusion rate of Rituximab & Obinutuzumab:** max 400 mg/h
1st dose: initial 50 mg/h, increase 50 mg/h every 30 mins (if no infusion reaction)
2nd and after dose: initial 100 mg/h, increase 100 mg/h every 30 mins (if no infusion reaction)

Polatuzumab vedotin-piiq + mosunetuzumab-axgb

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Mosunetuzumab	1 mg	≥ 4 hrs	d1	Q3W	1st	37
Polatuzumab vedotin-piiq	1.8 mg/kg	90 mins	d1	Q3W		
Mosunetuzumab	2 mg	≥ 4 hrs	d8	Q3W	1st	
Mosunetuzumab	60 mg	≥ 4 hrs	d15	Q3W	1st	
Followed by						
Mosunetuzumab	60 mg	≥ 2 hrs	d1	Q3W	2nd	
Polatuzumab vedotin-piiq	1.8 mg/kg	30 mins	d1	Q3W	2nd	
Followed by						
Mosunetuzumab	30 mg	≥ 2 hrs	d1	Q3W	3rd -6th	
Polatuzumab vedotin-piiq	1.8 mg/kg	30 mins	d1	Q3W	3rd -6th	
Followed by						
Mosunetuzumab	30 mg	≥ 2 hrs	d1	Q3W	7th and after	

Tafasitamab(CD19)+ Lenalidomide

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Tafasitamab	12 mg/kg	90-150 mins*	d1, 4,8, 15, 22	Q4W	1st	38
lenalidomide	25mg		d1-21	Q4W	1st	
Tafasitamab	12 mg/kg	90-120 mins*	d1,8, 15, 22	Q4W	2nd-3rd	
lenalidomide	25mg		d1-21	Q4W	2nd-3rd	
Tafasitamab	12 mg/kg	90-120 mins*	d1,15	Q4W	4th-12th	
lenalidomide	25mg		d1-21	Q4W	4th -12th	
Tafasitamab	12 mg/kg	90-120 mins*	d1,15	Q4W	13th and after	

* 70mL/h for the first 30 mins, then increase the rate

Glofitamab-gxbm + GemOx

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Obinutuzumab	1000 mg	★	d1	Q3W	1st	35
Gemcitabine	1000	30 mins	d2	Q3W	1st	
Oxaliplatin	100	2 hrs	d2	Q3W	1st	
Glofitamab	2.5 mg	≥ 4 hrs*	d8	Q3W	1st	
Glofitamab	10 mg	≥ 4 hrs*	d15	Q3W	1st	
Followed by						
Gemcitabine	1000	30 mins	d1	Q3W	2nd -8th	
Oxaliplatin	100	2 hrs	d1	Q3W	2nd -8th	
Glofitamab	30 mg	≥ 4 → 2 hrs*	d1	Q3W	2nd -8th	
Followed by						
Glofitamab	30 mg	2 hrs	d1	Q3W	9th-12th	

*over 4 hours in cycle 1&2, 2 hours in cycle 3-12

Epcoritamab-bysp + GemOx

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
Epcoritamab	0.16 mg SC		d1	Q4W	1st	36
Gemcitabine	1000	30 mins	d2	Q4W	1st	
Oxaliplatin	100	2 hrs	d2	Q4W	1st	
Epcoritamab	0.8 mg SC		d8	Q4W	1st	
Epcoritamab	48 mg SC		d15, 22	Q4W	1st	
Followed by						
Epcoritamab	48 mg SC		d1, 8, 15, 22	Q4W	2nd -3rd	
Gemcitabine	1000	30 mins	d1, 15	Q4W	2nd -3rd	
Oxaliplatin	100	2 hrs	d1, 15	Q4W	2nd -3rd	
Followed by						
Epcoritamab	48 mg SC		d1, 15	Q4W	4th	
Gemcitabine	1000	30 mins	d1, 15	Q4W	4th	
Oxaliplatin	100	2 hrs	d1, 15	Q4W	4th	
Followed by						
Epcoritamab	48 mg SC		d1, 15	Q4W	5th-9th	
Followed by						
Epcoritamab	48 mg SC		d1	Q4W	10th and after	

DHAP (Dexamethasone, Cisplatin, Cytarabine) ± Rituximab

藥品名	劑量 mg/m^2	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3-4W		12
Cisplatin	100	22-24 hrs	d1	Q3-4W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3-4W		
Dexamethasone	40 mg PO/IV	10-15 mins	d1-4	Q3-4W		

DHAX (Dexamethasone, Cytarabine, Oxaliplatin) ± Rituximab

藥品名★	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3W		25
Oxaliplatin	100	2 hr	d1	Q3W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3W		
Dexamethasone	40 mg	10-15 mins	d1-4	Q3W		

DHAX (Dexamethasone, Cytarabine, Carboplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q3W		32
Carboplatin	AUC5	1 hr	d1	Q3W		
Cytarabine	2000 Q12H	≥ 1 hr	d2	Q3W		
Dexamethasone	40 mg	10-15 mins	d1-4	Q3W		

GDP (Gemcitabine, Dexamethasone, Cisplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d8	Q3W		19
Gemcitabine	1000	30 mins	d1, 8	Q3W		
Dexamethasone	40 mg	10-15 mins	d1-4	Q3W		
Cisplatin	75	≥ 4 hrs	d1	Q3W		

GDP (Gemcitabine, Dexamethasone, Cisplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d8	Q3W		14
Gemcitabine	1000	30 mins	d1, 8	Q3W		
Dexamethasone	40 mg	10-15 mins	d1-4	Q3W		
Carboplatin	AUC 5	1 hr	d1	Q3W		

GemOx (Gemcitabine, Oxaliplatin) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q2W		15, 23
Gemcitabine	1000-1200	30 mins	d1	Q2W		
Oxaliplatin	100-120	2 hrs	d2	Q2W		

ICE (Ifosfamide, Carboplatin, Etoposide) ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
± Rituximab	375	★	d1	Q2W		12
Etoposide	100	30-60 mins	d1-3	Q2W		
Carboplatin	AUC 5	1 hr	d2	Q2W		
Isofamide	5000	24 hrs	d2	Q2W		

Bendamustine, Polatuzumab vedotin-piiq, ± Rituximab

藥品名	劑量 mg/m²	輸注時間	給藥日	頻率	週期	參考文獻
Polatuzumab vedotin-piiq	1.8 mg/kg	90 mins	d1	Q3W	6	28, 34
Bendamustine	90	30 mins	d1, 2	Q3W	6	
± Rituximab	375	★	d1	Q3W	6	

Anti-CD19 CAR T-cell therapy (only after ≥ 2 prior chemoimmunotherapy regimens)

Axicabtagene ciloleucel

Lisocabtagene maraleucel

參考文獻

1. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-2045.
2. Feugier P, Van hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de I'Adulte. J Clin Oncol 2005;23:4117-4126.
3. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.
4. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
5. Purroy N, Bergua J, Gallur L, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol 2015;169:188-198.
6. EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758-765.
7. Martino R, Perea G, Caballero MD, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study. Haematologica 2002;87:822-827.
8. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47:2174-2180.
9. Moccia A, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): Excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines [abstract]. Blood 2009;114:Abstract 408.
10. Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research

Institute trial. J Clin Oncol 2014;32:282-287.
11. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-468.
12. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
13. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829-1836.
14. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma 2010;51:1523-1529.
15. Lopez A, Gutierrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/ relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol 2008;80:127-132.
16. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
17. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna/ ifosfamide, mitoxantrone and etoposide for refractory lymphoms. Ann Oncol 1995;6(6):609-611.
18. Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia Group B multi-center study of DAEPOCH- rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012;97:758-765.
19. Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004;101:1835-1842.
20. Corazzelli G, Capobianco G, Arcamone M, et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009;64:907-916.

21. Maloney DG, Grillo= Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma.Blood 1997;90(6):2188-2195.
22. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363-1368.
23. Hiroaki A, Ippei S, Yasufumi M, et al. 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. Intern Med August 21, 2017.
24. Laribi K, Denizon N, Bolle D, et al. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol. 2016;95(10):1705–1714.
25. Julie Lignon, David Sibon,, et al.Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma & Leukemia, Vol. 10, No. 4, 262-269, 2010.
26. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902-1909.
27. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015;125:1394-1402.
28. Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (Pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study [abstract]. Blood 2018;132: Abstract 1683.
29. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922-926.
30. Neste, Andre Goy, Brian T. Hill, Catherine Thieblemont, et al. Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The Phase 2b Sadal Study. Blood 2018; 132 (Supplement 1): Abstract 1677
31. Salles G, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020. Published online June 5, 2020.
32. Tessoulin, B., Thomare, P., Delande, E. et al. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose

cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas. Ann Hematol 96, 943–950 (2017). https://doi.org/10.1007/s00277-017-2981-2.
33. Tilly H, Morschhauser F, Sehn L, et al Polatuzumab vedotin in previously untreated diffuse large B-cell therapy. N Eng J Med 2022;386:351-363.
34. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38:155-165.
35. Abramson JS, Ku M, Hertzberg M, et al. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet 2024;404:1940-1954.
36. Epcoritamab-bysp + GemOx Brody JD, Jørgensen J, Belada D, et al. Epcoritamab plus GemOx in transplant ineligible relapsed/ refractory DLBCL: Results from the EPCORE NHL-2 trial. Blood 2025;145:1621-1631
37. Budde LE, Olszewski AJ, Assouline S, et al. Mosunetuzumab with polatuzumab vedotin in relapsed orrefractory aggressive large B cell lymphoma: a phase 1b/2 trial. Nat Med 2024;30:229-239.
38. Salles G, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020.

《淋巴癌放射治療共識》

一、治療範圍

1. 淋巴腫瘤
2. 淋巴腫瘤侵犯高風險範圍

二、治療劑量 / 次數

1. 總劑量

▲何杰金氏淋巴癌：

(1) 非局部大型腫瘤：劑量 : 20-30 Gy, 次數 : 10-20 次 , 單次劑量 1.5-2.0 Gy
(2) 局部大型腫瘤：30-36Gy, 次數 : 15-20 次 , 單次劑量 1.5-2.0 Gy
(3) 化療後部分反應：36-40Gy, 次數 : 18-27 次 單次劑量 1.5-2.0 Gy

▲非何杰金氏淋巴癌 :

濾泡淋巴癌

(1) 劑量：24-30 Gy, 次數：12-20 次 , 單次劑量 1.5-2.0 Gy

早期被套細胞淋巴癌

(1) 劑量：24-36 Gy, 次數：12-20 次 , 單次劑量 1.5-2.0 Gy

邊緣區型淋巴癌

(1) 劑量：24Gy, 次數：12-16 次 , 單次劑量 1.5-2.0 Gy
(2) 胃部：24Gy, 次數：16 次 , 單次劑量 1.5 Gy

瀰漫性大型 B 細胞淋巴癌

(1) 化療後完全反應：劑量：30-36 Gy, 次數：15-24 次
(2) 化療後部分反應：劑量：36-50 Gy, 次數：18-34 次
(3) 對化療反應不佳或不適合化療：劑量：40-55Gy, 次數：20-37 次
(4) 與 stem cell transplantation 合併：劑量：20-36Gy, 次數：10-24 次

NK/T 細胞淋巴癌

(1) 單獨使用 RT：劑量：50-55 Gy, 次數：25-31 次 ,
(2) RT 合併其他治療：劑量：45-56Gy, 次數：22-32 次

周邊 T 細胞淋巴癌

(1) 化療後完全反應：劑量：30-36 Gy, 次數：15-20fx
(2) 化療後部分反應：劑量：40-50Gy, 次數：20-34fx
(3) 對化療反應不佳或不適合化療：劑量：40-55Gy, 次數：20-37fx
(4) 與 HCT 合併：劑量：20-36Gy, 次數：10-24fx

PCMZL & PCFCL

(1) 單獨使用 RT：劑量：24-30 Gy, 次數：12-17fx

MF & SS

(1) Individual plaque and tumor lesions：劑量：8-12 Gy, 次數：1-6fx
(2) Unilesional MF：劑量：24-30Gy, 次數：12-20fx
(3) TSEBT：劑量：12-36Gy, 次數：2-9fx, general 4-6 Gy per week

Primary cutaneous ALCL

(1) 治癒性劑量：劑量：24-30 Gy, 次數：12-20fx

Primary CNS Lymphoma

(1) 全腦放射線治療 劑量 : 20Gy-24Gy, 次數：10-16fx

(2) 考慮局部加強至 40-50Gy

Breast implant associated anaplastic large cell lymphoma, (BIA-ALCL)

(1) 局部殘留腫瘤 劑量 : 24-36Gy, 次數 : 15-20fx

三、治療方式：

使用強度調控放射治療技術，包含弧形及螺旋放射規畫，可考慮搭配影像導引治療，治療選擇可使用同步照射高與低危險部位的方式或先給予整個照射部位部份劑量照射後，再針對高危險部位加強劑量。

四、參考文獻：

1. International Commission on Radiation Units and Measurements. ICRU Report No 62: Prescribing, Recording and Reporting Photon Beam Therapy（Supplement to ICRU Report 50）. Bethesda, MD: ICRU Publications 1999.
2. Emami B, et al: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-22.
3. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. International journal of radiation oncology, biology, physics 2010; 76(3 Suppl): S3-9.
4. Marc P.E. André, Théodore Girinsky, Massimo Federico, et al. Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of Clinical Oncology 2017 35:16, 1786-1794
5. NCCN clinical practice guidelines in oncology for Hodgkin lymphoma, version 1.2026, website: www.nccn.org
6. NCCN clinical practice guidelines in oncology for B-Cell lymphomas, version 3.2025, website: www.nccn.org
7. NCCN clinical practice guidelines in oncology for Primary Cutaneous Lymphomas, version 3.2025, website: www.nccn.org
8. NCCN clinical practice guidelines in oncology for T-Cell lymphomas, version 2.2025, website: www.nccn.orgwww.nccn.org
9. NCCN clinical practice guidelines in oncology for Central Nervous System Cancers, version 2.2025, website: www.nccn.org